The effect of hydroalcoholic extract of Berberis fruits integerrima on the lipid profile, antioxidantparameters and liver and kidney function tests in patients with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190714044196N1

Enrollment

Registered

2019-07-31

Start date

2017-10-17

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: received a gelatin capsule contain 750 mg hydro-alcoholic extract of Berberis integerrima . Berberis fruits were taken from mountainous areas of Bardsir, Kerman, So

Eligibility

Sex/Gender

All

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Suffering from nonalcoholic fatty liver Elevated levels of Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Age range of 20-45 years old Signing a declaration of consent

Exclusion criteria

Exclusion criteria: Using alcohol Using daily berberis Having allergy to berberis and its compounds, Patients with diabetes High blood pressure Patient with perceptual disorders Nephrotic syndrome Ischemic heart diseases Patient with chronic liver disease such as hepatitis Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Total cholesterol. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Triglyceride. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;LDL-C. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;HDL-C. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Alanine aminotransferase. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Aspartate aminotransferase. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Alkaline phosphatase. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Total bilirubin. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;And direct bilirubin. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Urea. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Creatinine. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Glutathione peroxidase enzyme. Timepoint: Before and after treatment. Method of measurement: ZellBio kit.;Malondialdehyde. Timepoint: Before and after treatment. Method of measurement: ZellBio kit.;Total antioxidant. Timepoint: Before and after treatment. Method of measurement: ZellBio kit.;Blood pressure. Timepoint: Before and after treatment. Method of measurement: Blood pressure monitor.	—

Measure

Time frame

Fasting blood glucose. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Total cholesterol. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Triglyceride. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;LDL-C. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;HDL-C. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Alanine aminotransferase. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Aspartate aminotransferase. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Alkaline phosphatase. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Total bilirubin. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;And direct bilirubin. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Urea. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Creatinine. Timepoint: Before and after treatment. Method of measurement: measured using Pars azmun kit.;Glutathione peroxidase enzyme. Timepoint: Before and after treatment. Method of measurement: ZellBio kit.;Malondialdehyde. Timepoint: Before and after treatment. Method of measurement: ZellBio kit.;Total antioxidant. Timepoint: Before and after treatment. Method of measurement: ZellBio kit.;Blood pressure. Timepoint: Before and after treatment. Method of measurement: Blood pressure monitor.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Afshari

Rafsanjan University of Medical Sciences

mehdi.af.1372@gmail.com+98 34 3131 5175

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026